

Claims 1-3, 7-13 and claim 22 have been amended, and the marked-up version of these claims appears as an appendix to this document.

Claims 15-21 have been deleted.

Claims 23-35 have been added.

The amended and added claims are all supported in the original specification and in the original Preliminary Amendment filed 08/03/2001.


It is respectfully requested that all amended and new claims, as well as the amended title, be entered.

A duplicate copy of the claim fee calculation sheet filed 08/03/01 is enclosed.

Date:

08/21/01

Respectfully submitted,



Melvin Blecher, PhD
Attorney-at-Law
Reg. No. 33,649 I

Law Offices of Dr. Melvin Blecher
4329 Van Ness Street, NW
Washington, DC 20016-5625
tel: 202-363-3338
fax: 202-362-8404



VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

AUG 24 2001

RECEIVED

TECH CENTER 1600P300

- I. A [dietary] composition with synergistic anti-inflammatory properties for use in human conditions induced by inflammatory biomolecules released from mast cells by the activation and degranulation of mast cells [secretion and consequent degranulation of said cells and release of inflammatory biomolecules from said cells], comprising a non-bovine proteoglycan [sulfate,] and [, optionally,] one or more of a hexosamine sulfate, a [flavone] flavonoid [an organic extra virgin kernel seed olive oil], S-adenosylmethionine, [and diphenhydramine] a histamine-1-receptor antagonist and kernel olive oil, in an appropriate excipient or vehicle for oral or topical administration.
2. The composition according to claim 1, wherein said [sulfated] proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic acid.
3. The composition according to claim 2, wherein said chondroitin sulfate [chondroitin sulfate C] is derived from shark cartilage.
5. The composition according to claim 1, wherein said [flavone] flavonoid is selected from the group consisting of quercetin, myricetin, genistein and kaempferol.
7. The [A] composition[for treating inflammatory diseases] according to claim 1, said composition being for parenteral use, comprising 300 mg each of non-bovine chondroitin sulfate C, quercetin and D-glucosamine sulfate, with an organic extra virgin kernel seed olive oil containing omega fatty acids and alpha tocopherol.
8. The composition according to claim 7 or 24, further supplemented with 100 mg of S-adenosylmethionine.
9. The [A] composition[for treating inflammatory diseases] according to claim 1, said composition consisting of an ointment or cream for topical application, comprising, in mg % , chondroitin sulfate, 5, and[, optionally,] one or more of D-glucosamine sulfate, 5; quercetin, 3; and, extra virgin kernel seed olive oil, 15.
10. The [A] composition according to claim 9, supplemented by the histamine-1-receptor antagonist diphenhydramine, 5mg%.
11. The [A] composition [for treating inflammatory diseases] according to claim 1, said composition consisting of a mouth wash composition, comprising chondroitin sulfate, 0.4M, and [,optionally,] one or more of D-glucosamine sulfate, 0.4M, quercetin, 0.3M, and S-adenosylmethionine, 0.15M, in a mouth wash vehicle.
12. The [A] composition [for treating inflammatory diseases] according to claim 1, said composition consisting of a tooth paste, comprising, in mg%, chondroitin sulfate, 5, and one

or more of D-glucosamine sulfate, 5, and quercetin, 3, in a tooth paste vehicle.

13. The [A] composition [for treating inflammatory diseases] according to claim 1, said composition consisting of a sunscreen [composition], comprising, in mg%, chondroitin sulfate, 5, and [, optionally,] one or more of D-glucosamine sulfate, 5, quercetin, 3, and titanium dioxide, 5, in a sun screen vehicle.

22. The [A] method of treating a subject suffering from an inflammatory disease resulting from activation and degranulation of mast cells and secretion of inflammatory molecules from said cells, said inflammatory diseases selected from the group consisting of osteoarthritis, cancer, fibromyalgia, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, migraines, angina, chronic prostatitis, eczema, arthritis, multiple sclerosis, psoriasis, sun burn, and periodontal disease, comprising the step of administering to said subject an effective amount of a composition according to claim 1.



VERSION WITH MARKINGS TO SHOW CHANGES TO TITLE

Synergistic Proteoglycan Compositions for [Treatment of] Inflammatory Diseases